Jagsonpal Pharmaceuticals Limited (JAGSNPHARM.BO)
INR 688.55
(0.19%)
INR 688.55
(0.19%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.08 Billion INR | -11.83% |
| 2022 | 2.36 Billion INR | 8.79% |
| 2021 | 2.17 Billion INR | 15.77% |
| 2020 | 1.87 Billion INR | 18.53% |
| 2019 | 1.58 Billion INR | -4.95% |
| 2018 | 1.66 Billion INR | 31.84% |
| 2017 | 1.26 Billion INR | -12.05% |
| 2016 | 1.43 Billion INR | 0.27% |
| 2015 | 1.43 Billion INR | 3.86% |
| 2014 | 1.38 Billion INR | -3.96% |
| 2013 | 1.43 Billion INR | -13.58% |
| 2012 | 1.66 Billion INR | -5.69% |
| 2011 | 1.76 Billion INR | 9.67% |
| 2010 | 1.6 Billion INR | 15.3% |
| 2009 | 1.39 Billion INR | 2.49% |
| 2008 | 1.36 Billion INR | -9.26% |
| 2007 | 1.5 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 614.39 Million INR | 41.28% |
| 2024 Q2 | 746.92 Million INR | 21.57% |
| 2023 Q1 | 601.53 Million INR | 8.47% |
| 2023 Q2 | 578.29 Million INR | -3.86% |
| 2023 Q3 | 472.34 Million INR | -18.32% |
| 2023 FY | 2.08 Billion INR | -11.83% |
| 2023 Q4 | 434.86 Million INR | -7.93% |
| 2022 Q3 | 601.4 Million INR | -0.64% |
| 2022 Q1 | 605.97 Million INR | 16.23% |
| 2022 FY | 2.36 Billion INR | 8.79% |
| 2022 Q4 | 554.54 Million INR | -7.79% |
| 2022 Q2 | 605.26 Million INR | -0.12% |
| 2021 Q4 | 521.35 Million INR | -3.29% |
| 2021 FY | 2.17 Billion INR | 15.77% |
| 2021 Q3 | 539.09 Million INR | -7.68% |
| 2021 Q2 | 583.93 Million INR | 8.03% |
| 2021 Q1 | 540.54 Million INR | 26.4% |
| 2020 FY | 1.87 Billion INR | 18.53% |
| 2020 Q3 | 571.04 Million INR | 1.33% |
| 2020 Q2 | 563.52 Million INR | 78.04% |
| 2020 Q1 | 316.52 Million INR | 7.23% |
| 2020 Q4 | 427.66 Million INR | -25.11% |
| 2019 Q4 | 295.17 Million INR | -29.74% |
| 2019 FY | 1.58 Billion INR | -4.95% |
| 2019 Q1 | 452.34 Million INR | 17.79% |
| 2019 Q3 | 420.1 Million INR | 0.49% |
| 2019 Q2 | 418.05 Million INR | -7.58% |
| 2018 Q1 | 424.04 Million INR | 29.78% |
| 2018 Q2 | 441.24 Million INR | 4.06% |
| 2018 Q3 | 418.94 Million INR | -5.05% |
| 2018 Q4 | 384.02 Million INR | -8.34% |
| 2018 FY | 1.66 Billion INR | 31.84% |
| 2017 Q1 | 268.96 Million INR | -8.39% |
| 2017 Q4 | 326.73 Million INR | -14.15% |
| 2017 Q3 | 380.56 Million INR | 31.65% |
| 2017 Q2 | 289.06 Million INR | 7.47% |
| 2017 FY | 1.26 Billion INR | -12.05% |
| 2016 Q1 | 401.1 Million INR | 3.06% |
| 2016 FY | 1.43 Billion INR | 0.27% |
| 2016 Q2 | 400.19 Million INR | -0.23% |
| 2016 Q3 | 343.82 Million INR | -14.08% |
| 2016 Q4 | 293.58 Million INR | -14.61% |
| 2015 FY | 1.43 Billion INR | 3.86% |
| 2015 Q4 | 389.2 Million INR | 12.45% |
| 2015 Q3 | 346.1 Million INR | 4.98% |
| 2015 Q2 | 329.69 Million INR | -10.87% |
| 2015 Q1 | 369.88 Million INR | -4.79% |
| 2014 Q3 | 324.28 Million INR | -1.61% |
| 2014 Q2 | 329.6 Million INR | -2.81% |
| 2014 Q1 | 339.13 Million INR | 8.42% |
| 2014 FY | 1.38 Billion INR | -3.96% |
| 2014 Q4 | 388.48 Million INR | 19.8% |
| 2013 Q1 | 380.78 Million INR | -0.14% |
| 2013 Q2 | 367.89 Million INR | -3.39% |
| 2013 Q4 | 312.8 Million INR | -17.03% |
| 2013 Q3 | 377.01 Million INR | 2.48% |
| 2013 FY | 1.43 Billion INR | -13.58% |
| 2012 Q1 | 372.26 Million INR | -10.21% |
| 2012 Q2 | 417.83 Million INR | 12.24% |
| 2012 Q3 | 493.21 Million INR | 18.04% |
| 2012 Q4 | 381.33 Million INR | -22.68% |
| 2012 FY | 1.66 Billion INR | -5.69% |
| 2011 FY | 1.76 Billion INR | 9.67% |
| 2011 Q3 | 465.96 Million INR | -2.22% |
| 2011 Q2 | 476.54 Million INR | 0.0% |
| 2011 Q4 | 414.61 Million INR | -11.02% |
| 2010 FY | 1.6 Billion INR | 15.3% |
| 2009 FY | 1.39 Billion INR | 2.49% |
| 2008 FY | 1.36 Billion INR | -9.26% |
| 2007 FY | 1.5 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Ajanta Pharma Limited | 42.08 Billion INR | 95.041% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 50.454% |
| Sigachi Industries Limited | 3.98 Billion INR | 47.688% |
| Bal Pharma Limited | 3.39 Billion INR | 38.476% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 83.707% |
| Medico Remedies Limited | 1.44 Billion INR | -44.011% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -100.031% |
| Venus Remedies Limited | 5.91 Billion INR | 64.713% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -176.261% |
| Alpa Laboratories Limited | 1.08 Billion INR | -91.929% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 87.607% |
| Shilpa Medicare Limited | 11.51 Billion INR | 81.877% |
| Aarti Drugs Limited | 25.28 Billion INR | 91.746% |
| Lupin Limited | 200.1 Billion INR | 98.957% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 99.273% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 98.903% |
| Windlas Biotech Limited | 6.3 Billion INR | 66.923% |
| Suven Life Sciences Limited | 116.92 Million INR | -1684.861% |
| Eris Lifesciences Limited | 20.09 Billion INR | 89.612% |
| Valiant Laboratories Limited | 1.82 Billion INR | -14.635% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 94.01% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 83.147% |
| Ipca Laboratories Limited | 76.22 Billion INR | 97.262% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 72.904% |
| Achyut Healthcare Limited | 61.36 Million INR | -3300.772% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.57% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 55.916% |
| RPG Life Sciences Limited | 5.82 Billion INR | 64.144% |
| Mankind Pharma Limited | 103.34 Billion INR | 97.981% |
| Laurus Labs Limited | 50.01 Billion INR | 95.827% |
| Piramal Pharma Limited | 81.71 Billion INR | 97.446% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | 19.496% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 98.032% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 96.585% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 98.233% |
| Unichem Laboratories Limited | 16.57 Billion INR | 87.408% |
| Sequent Scientific Limited | 13.69 Billion INR | 84.763% |
| Novartis India Limited | 3.35 Billion INR | 37.714% |
| Wanbury Limited | 5.75 Billion INR | 63.745% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 80.149% |
| Wockhardt Limited | 27.89 Billion INR | 92.517% |
| Themis Medicare Limited | 3.81 Billion INR | 45.332% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 96.886% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 90.859% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 99.252% |
| Divi's Laboratories Limited | 78.45 Billion INR | 97.34% |
| NATCO Pharma Limited | 40.02 Billion INR | 94.785% |
| Gufic Biosciences Limited | 8.06 Billion INR | 74.128% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 90.151% |
| Ind-Swift Limited | 5.02 Billion INR | 58.465% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 81.872% |
| FDC Limited | 19.42 Billion INR | 89.258% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -313.915% |
| Granules India Limited | 45.06 Billion INR | 95.369% |
| Medicamen Biotech Limited | 1.79 Billion INR | -16.394% |
| Alkem Laboratories Limited | 126.67 Billion INR | 98.352% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 83.891% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -421.295% |
| Brooks Laboratories Limited | 794.86 Million INR | -162.564% |
| Megasoft Limited | 373.95 Million INR | -458.097% |
| ZIM Laboratories Limited | 3.67 Billion INR | 43.199% |
| Strides Pharma Science Limited | 40.51 Billion INR | 94.848% |
| Neuland Laboratories Limited | 15.58 Billion INR | 86.609% |
| Morepen Laboratories Limited | 17.01 Billion INR | 87.737% |
| Hikal Limited | 17.84 Billion INR | 88.305% |
| Indoco Remedies Limited | 17.89 Billion INR | 88.337% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 88.504% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -35.194% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | 43.379% |
| Hester Biosciences Limited | 3.04 Billion INR | 31.471% |